The difference between a job and a career is what you walk away with when it ends. Here's how to evaluate if your role and ...

The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...

Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a ...

The Commissioner’s National Priority Voucher program was launched in June to shorten review times for companies that align ...

With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.

Pfizer deals again in obesity space as Wave and Structure drop splashy weight loss results; what CDER Director Richard Pazdur’s sudden retirement means for biopharma; neuro diseases take center stage ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

At the heart of the deal is Relation’s Lab-in-the-Loop platform, which uses AI models to improve understanding of diseases ...

Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week ...